Andy Gordon
Co-Founder, Early Investing

Andy has three decades of experience in the private and public sectors as an entrepreneur and advisor. The CIA, former Maryland Governor William Donald Schaefer, and Fortune 500 companies such as Lockheed Martin and Dow Chemical have all trusted his advice. Andy founded and ran an international trade and finance company based in Asia. Upon returning to the U.S., he joined a Florida investment advisory service that quickly gained a reputation for recommending companies with outstanding value and fundamentals. Andy has taught marketing and finance courses at local Maryland universities and has written a half-dozen books on global business, published by McGraw-Hill, Frost & Sullivan and others. He now regularly shares his worldly knowledge about investing in startups, cryptocurrency and cannabis with everyday investors in the free daily e-letter, Early Investing.
Articles by Andy Gordon
The Five Metrics Startup Investors Are Most Likely to Get Wrong
December 4, 2019
Early investors have few metrics to go by when evaluating potential startup investments. Here are five metrics, in particular, that investors often misconstrue.
The Five Future Disruptions I’m Already Grateful For
November 27, 2019
It’s almost Thanksgiving, so here are five future disruptive technologies that Andy Gordon is already thankful for.
Quantum Computing Is (Almost) Here
November 20, 2019
No industry is safe from disruption. Including computers. Quantum computing is the next big disruption… and it may be closer than you think.
Two Ways to Resolve the Opioid Crisis
November 13, 2019
More than 400,000 Americans have died from opioid overdoses. But there’s a solution – and two different methods to approach it.
The Deep, Dark Hole of Drug Addiction
November 6, 2019
The opioid crisis has taken thousands of lives. And Andy Gordon has experienced the damage firsthand. But there is hope for a better future.
The Opioid Crisis Cost Us Almost $200 Billion Last Year
October 30, 2019
The opioid crisis has cost American families, employers and the government billions of dollars. And we’re just beginning to see drug companies be held accountable. But there’s a silver lining.
China’s Industrial Espionage Is Bad Policy
October 23, 2019
China is in the news again for industrial espionage. And it’s a reflection of how far off course the country has gotten.
Why Big Budgets Can Lead to Low Returns
October 16, 2019
The most successful IPOs over the past decade all have one thing in common. And it’s not revenue growth.